The Kit Taylor Memorial Fund brought us another informative evening through Dr. Jennifer Taylor-Cousar’s presentation entitled “CF Therapeutics: Great Strides & Future Directions.” Dr. Taylor-Cousar is the Medical Director of Clinical Research Services at National Jewish Health and also serves as Director of CF Therapeutics Development and Co-Director of the Adult CF Program. Her credentials were evident in the range of information shared in the lecture.
The lecture host, URMC Department of Pediatrics, has provided us with a recording of the event. You can view the recording by clinking this link: 2022 Kit Taylor Memorial Lecture. The program runs a little less than an hour. Here are some tips for watching the lecture.
There was a glitch in launching the recording so the first few minutes of the lecture are not covered. Don’t worry – there is plenty of information for you to ponder. However, a couple of critical items are not included.
Dr. Karen Voter, Director of the Pediatric Care for the Rochester CF Center, introduced the program with Kit Taylor’s story. The insights in Kit’s diary continue to provide the inspiration for the Memorial Lecture series.
Consistent with professional standards, Dr. Taylor-Cousar began her presentation with disclosure of her connections with organizations and businesses. Those relationships are noted in Dr Taylor-Cousar Disclosures.
As noted earlier, Dr. Taylor-Cousar’s lecture is loaded with information. Fortunately, you can pause and rewind the video so you don’t miss anything of interest to you. You will hear plenty of references to ETI or ElxTezIva. These are short hand references to CFTR modulator formula of Elexacaftor/Tezacaftor/Ivacaftor, better known by the tradename Trikafta.
Dr. Taylor-Cousar wrapped up her discussion with a demonstration of her take on the Cystic Fibrosis Foundation slogan: “Until it’s done for everyone.” She spoke about the ongoing research for treatments for individuals who do not benefit from CFTR modulators. She also noted the increased attention being given to non-white populations who were historically overlooked based on the assumption that CF was specific to European descendants.
A big thank you to the Kit Taylor Memorial Fund and the URMC Department of Pediatrics for continuing the tradition of relevant presentations in the Kit Taylor Memorial Lecture series.